Sera Prognostics, Inc. (NASDAQ:SERA) Shares Sold by Vivo Capital LLC

Vivo Capital LLC cut its holdings in Sera Prognostics, Inc. (NASDAQ:SERA - Free Report) by 11.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,650,440 shares of the company's stock after selling 205,571 shares during the period. Sera Prognostics makes up 0.8% of Vivo Capital LLC's portfolio, making the stock its 26th largest position. Vivo Capital LLC owned 5.27% of Sera Prognostics worth $9,870,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Perigon Wealth Management LLC bought a new stake in Sera Prognostics in the 4th quarter worth $509,000. CWM LLC purchased a new position in Sera Prognostics during the 4th quarter valued at about $242,000. Vanderbilt University bought a new position in Sera Prognostics during the 4th quarter valued at approximately $284,000. Finally, Resource Consulting Group Inc. purchased a new stake in Sera Prognostics in the 4th quarter worth approximately $265,000. 54.64% of the stock is currently owned by hedge funds and other institutional investors.

Sera Prognostics Stock Up 5.3 %

Shares of SERA traded up $0.49 during mid-day trading on Thursday, hitting $9.79. 99,198 shares of the company's stock traded hands, compared to its average volume of 213,659. The business's 50-day moving average price is $9.67 and its 200-day moving average price is $6.69. Sera Prognostics, Inc. has a 1 year low of $1.52 and a 1 year high of $12.35. The firm has a market capitalization of $317.49 million, a P/E ratio of -8.59 and a beta of 1.33.

Sera Prognostics (NASDAQ:SERA - Get Free Report) last issued its quarterly earnings data on Wednesday, March 20th. The company reported ($0.25) EPS for the quarter, hitting the consensus estimate of ($0.25). The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.10 million. Sera Prognostics had a negative net margin of 11,843.79% and a negative return on equity of 45.74%. Sell-side analysts anticipate that Sera Prognostics, Inc. will post -0.94 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Austin Aerts sold 8,092 shares of the stock in a transaction that occurred on Tuesday, March 26th. The stock was sold at an average price of $9.37, for a total value of $75,822.04. Following the completion of the transaction, the chief financial officer now owns 322,488 shares of the company's stock, valued at approximately $3,021,712.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, CFO Austin Aerts sold 8,092 shares of the business's stock in a transaction dated Tuesday, March 26th. The shares were sold at an average price of $9.37, for a total transaction of $75,822.04. Following the sale, the chief financial officer now owns 322,488 shares of the company's stock, valued at $3,021,712.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider John J. Boniface sold 24,474 shares of the company's stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $9.04, for a total transaction of $221,244.96. Following the completion of the sale, the insider now owns 139,771 shares in the company, valued at approximately $1,263,529.84. The disclosure for this sale can be found here. Insiders sold 92,903 shares of company stock worth $866,284 over the last three months. Company insiders own 15.80% of the company's stock.

Sera Prognostics Company Profile

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.